Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2011

Primary Completion Date

December 31, 2017

Conditions
CarcinomaAdenocarcinomaUterine Cervix Adenosquamous Carcinoma
Interventions
DRUG

Nimotuzumab

Nimotuzumab, 200 mg, IV, Weekly doses for 14 weeks

DRUG

Cisplatin

Cisplatin, 40 mg/m2, IV, Weekly doses for 6 weeks

RADIATION

Brachytherapy

"Brachytherapy: 40 Gy at spot A(low dose rate, Intracavitary, 1 or 2 separate fractions for 1 to 3 weeks.~Brachytherapy: 28 Gy at spot A (high dose rate), Intracavitary 4 fractions of 7.0 Gy once or twice a week."

DRUG

Cisplatin

Cisplatin, 40 mg/m2, IV. Weekly doses for 6 weeks

RADIATION

Radiation Therapy

"Pelvic radiation therapy: 45 Gy, External, Fractions of 1.8 Gy per day, 5 days a week.~Dose boosts: 15 Gy ± 5%, External, Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week.~Brachytherapy 40 Gy at spot A(low dose rate.) Intracavitary 1 or 2 separate fractions for 1 to 3 weeks.~28 Gy at spot A (high dose rate, Intracavitary, 4 fractions of 7.0 Gy once or twice a week"

Trial Locations (7)

13083970

Caism - Unicamp, Campinas

17210000

Centro de Pesquisas Clínicas da Fundação Amaral Carvalho, Jaú

59075740

Centro de Pesquisa Clínica da Liga Norte Riograndense contra o Câncer, Natal

98700000

Hospital de Caridade de Ijui - ONCOSITE Centro de Pesquisa Clínica em Oncologia, Ijuí

90020-160

Hospital Santa Rita - Núcleo de Novos Tratamentos em Câncer, Porto Alegre

01246000

ICESP, São Paulo

08270070

Hospital Santa Marcelina, São Paulo

Sponsors
All Listed Sponsors
lead

Eurofarma Laboratorios S.A.

INDUSTRY